CD154 peptides and methods of reducing inflammation
AssigneeOp-T LLC
InventorDavid Wagner
Life of this patent
Estimating the term…
Loading patent…
AssigneeOp-T LLC
InventorDavid Wagner
Estimating the term…
The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which is important in inflammation. The present invention also relate to the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present invention also relates to the use of such short peptides to prevent or reverse autoimmune disease, and particular, diabetes, in individuals suffering from such disease. It also relates to methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells.
A method of inhibiting type 1 diabetes in a subject, the method comprising administering to the subject a peptide that binds a CD40 protein at the CD154-binding site and thereby inhibits type 1 diabetes, wherein the peptide is a peptide of 15 amino acids in length comprising the amino acid sequence of SEQ ID NO:27.
Dependencies are inferred from the claim text.